New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings

被引：96

作者：

Ocio, Enrique M. ^{[1
,2
]}

Mateos, Maria-Victoria ^{[1
]}

Maiso, Patricia ^{[2
]}

Pandiella, Antonasio ^{[2
]}

San-Miguel, Jesus F. ^{[1
,2
]}

机构：

[1] Hosp Univ Salamanca, Serv Hematol, Salamanca 37007, Spain

[2] Univ Salamanca, CIC, Inst Biol Mol & Celular Canc, Natl Res Council,CSIC, E-37008 Salamanca, Spain

来源：

LANCET ONCOLOGY | 2008年 / 9卷 / 12期

关键词：

D O I：

10.1016/S1470-2045(08)70304-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The outcome of multiple myeloma has substantially improved over the past decade, mainly due to recently approved drugs, such as thalidomide, lenalidomide, and bortezomib. Nevertheless, most patients still relapse and, therefore, drugs with new mechanisms of action are urgently needed to overcome this resistance. In this Review, we discuss some of the new targeted therapeutic strategies under assessment in preclinical and clinical studies in multiple myeloma. Unfortunately, the single-agent clinical activity of most of these new drugs has been limited; nevertheless, their effectiveness might be enhanced by their rational combination with each other or with conventional agents.

引用

页码：1157 / 1165

页数：9

共 71 条

[1] Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma [J].

Alsina, M ;

Fonseca, R ;

Wilson, EF ;

Belle, AN ;

Gerbino, E ;

Price-Troska, T ;

Overton, RM ;

Ahmann, G ;

Bruzek, LM ;

Adjei, AA ;

Kaufmann, SH ;

Wright, JJ ;

Sullivan, D ;

Djulbegovic, B ;

Cantor, AB ;

Greipp, PR ;

Dalton, WS ;

Sebti, SM .

BLOOD, 2004, 103 (09) :3271-3277

[2]

ALSINA M, 2007, BLOOD, V110

[3] Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma [J].

Annunziata, Christina M. ;

Davis, R. Eric ;

Demchenko, Yulia ;

Bellamy, William ;

Gabrea, Ana ;

Zhan, Fenghuang ;

Lenz, Georg ;

Hanamura, Ichiro ;

Wright, George ;

Xiao, Wenming ;

Dave, Sandeep ;

Hurt, Elaine M. ;

Tan, Bruce ;

Zhao, Hong ;

Stephens, Owen ;

Santra, Madhumita ;

Williams, David R. ;

Dang, Lenny ;

Barlogie, Bart ;

Shaughnessy, John D., Jr. ;

Kuehl, W. Michael ;

Staudt, Louis M. .

CANCER CELL, 2007, 12 (02) :115-130

[4]

ARNULF G, 2007, BLOOD, V110

[5]

Badros A, 2007, BLOOD, V110

[6]

Bahlis NJ, 2002, CLIN CANCER RES, V8, P3658

[7] A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6 [J].

Baughn, Linda B. ;

Di Liberto, Maurizio ;

Wu, Kaida ;

Toogood, Peter L. ;

Louie, Tracey ;

Gottschalk, Rachel ;

Niesvizky, Ruben ;

Cho, Hearn ;

Ely, Scott ;

Moore, Malcolm A. S. ;

Chen-Kiang, Selina .

CANCER RESEARCH, 2006, 66 (15) :7661-7667

[8]

Bensinger W., 2007, BLOOD, V110

[9] A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma [J].

Berenson, James R. ;

Matous, Jeffrey ;

Swift, Regina A. ;

Mapes, Russell ;

Morrison, Blake ;

Yeh, Howard S. .

CLINICAL CANCER RESEARCH, 2007, 13 (06) :1762-1768

[10] Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study [J].

Berenson, James R. ;

Boccia, Ralph ;

Siegel, David ;

Bozdech, Marek ;

Bessudo, Alberto ;

Stadtmauer, Edward ;

Pomeroy, J. Talisman ;

Steis, Ronald ;

Flam, Marshall ;

Lutzky, Jose ;

Jilani, Syed ;

Volk, Joseph ;

Wong, Siu-Fun ;

Moss, Robert ;

Patel, Ravi ;

Ferretti, Delina ;

Russell, Kit ;

Louie, Robert ;

Yeh, Howard S. ;

Swift, Regina A. .

BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (02) :174-183

← 1 2 3 4 5 6 7 8 →